Hostname: page-component-5db58dd55d-htx7c Total loading time: 0 Render date: 2026-06-14T15:49:11.249Z Has data issue: false hasContentIssue false
  • English
  • Français

Input from our Readers

Published online by Cambridge University Press:  07 November 2014

Marc N. Potenza ,
Christopher J. McDougle  and
Christian Rück
Marc N. Potenza
Affiliation:
Department of Psychiatry, Yale University School of Medicine, New Haven, CT
Christopher J. McDougle
Affiliation:
Indiana University School of Medicine, Indianapolis, IN
Christian Rück
Affiliation:
Department of Psychiatry, Karolinska Hospital and Institute, Stockholm, Sweden
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Information

Type
Letters to the Editor
Information
CNS Spectrums , Volume 3 , Issue 9: Trichotillomania: A New Understanding , October 1998 , pp. 22 - 23
Copyright
Copyright © Cambridge University Press 1998

References

REFERENCES

1.Hollander, E, Cartwright, C, Wong, CM, et al.A dimensional approach to the autism spectrum. CNS pectrum. 1998;3(3):22–39.CrossRefGoogle Scholar
2.McDougle, CJ, Brodkin, ES, Naylor, ST, Carlson, DC, Cohen, DJ, Price, LH. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol. 1998;18:62–66.Google Scholar
3.Potenza, MN, McDougle, CJ. The role of serotonin in autism spectrum disorders. CNS Spectrums. 1998;2(5):25–42.Google Scholar
4.Kapur, S, Remington, G. Serntonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry. 1996;153:466–476.Google Scholar
5.Potenza, MN, Holmes, JP, Kanes, SJ, McDougle, CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. In press.Google Scholar
6.McDougle, CJ, Holmes, JP, Branson, MR, et al.Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Psychiatry. 1997;36:685–693.Google Scholar
7.McDougle, CJ, Holmes, JP, Carlson, DC, Pelton, GH, Cohen, DJ, Price, LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55(7):633–641.Google Scholar
1.Weissman, M. Cross-national epidemiology of obsessive-compulsive disorder. CNS Spectrums. 1998;3(suppl 1):6–9.Google Scholar
2.Karno, M, Golding, J, Sorenson, S, Burnam, M. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry. 1988;45:1094–1099.Google Scholar
3.Robins, L, Helzer, J, Croughan, J, Ratcliff, K. National Institute of Mental Health diagnostic interview schedule: its history, characteristics, and validity. Arch Gen Psychiatry. 1981;38:381–389.CrossRefGoogle ScholarPubMed
4.Nelson, E, Rice, J. Stability of diagnosis of obsessive-compulsive disorder in the epidemiologic catchment area study. Am J Psychiatry. 1997;154:826–831.Google Scholar
5.Stein, M, Forde, D, Anderson, G, Walker, J. Obsessive-compulsive disorder in the community: an epidemiologic survey with clinical reappraisal. Am J Psychaitry. 1997;154:1120–1126.Google ScholarPubMed
6.Robins, L, Wing, J, Wittchen, H, et al.The composite international diagnostic interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. Arch Gen Psychiatry. 1988;45:1069–1077.Google Scholar